PriceTargets.com logo

RenovoRx - RNXT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.13
  • Forecasted Upside: 406.20%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.21 As of 11/20/2024 01:00 AM ET
▲ +0.1 (9.01%)

This chart shows the closing price for RNXT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New RenovoRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RNXT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RNXT

Analyst Price Target is $6.13
▲ +406.20% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for RenovoRx in the last 3 months. The average price target is $6.13, with a high forecast of $8.25 and a low forecast of $4.00. The average price target represents a 406.20% upside from the last price of $1.21.

This chart shows the closing price for RNXT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in RenovoRx. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/12/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$8.00 ➝ $8.25
6/17/2024Ascendiant Capital MarketsInitiated CoverageBuy$8.00
2/2/2024Alliance Global PartnersInitiated CoverageBuy$4.00
11/15/2023Maxim GroupReiterated RatingBuy ➝ Hold
8/18/2023Roth MkmLower TargetBuy ➝ Buy$14.00 ➝ $13.00
11/1/2021Roth CapitalInitiated CoverageBuy$16.00
10/6/2021Maxim GroupInitiated CoverageBuy$15.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

RenovoRx logo
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Read More

Today's Range

Now: $1.21
Low: $1.13
High: $1.24

50 Day Range

MA: $1.04
Low: $0.90
High: $1.22

52 Week Range

Now: $1.21
Low: $0.53
High: $2.35

Volume

249,694 shs

Average Volume

30,371 shs

Market Capitalization

$29.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of RenovoRx?

The following Wall Street analysts have issued reports on RenovoRx in the last twelve months: Alliance Global Partners, and Ascendiant Capital Markets.
View the latest analyst ratings for RNXT.

What is the current price target for RenovoRx?

0 Wall Street analysts have set twelve-month price targets for RenovoRx in the last year. Their average twelve-month price target is $6.13, suggesting a possible upside of 406.2%. Ascendiant Capital Markets has the highest price target set, predicting RNXT will reach $8.25 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $4.00 for RenovoRx in the next year.
View the latest price targets for RNXT.

What is the current consensus analyst rating for RenovoRx?

RenovoRx currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RNXT will outperform the market and that investors should add to their positions of RenovoRx.
View the latest ratings for RNXT.

What other companies compete with RenovoRx?

Other companies that are similar to RenovoRx include FibroGen, Cyclo Therapeutics, NanoViricides, Inhibikase Therapeutics and CalciMedica. Learn More about companies similar to RenovoRx.

How do I contact RenovoRx's investor relations team?

RenovoRx's physical mailing address is 333 W. SANTA CLARA STREET SUITE 900, SAN JOSE CA, 95110. The company's listed phone number is 650-284-4433 and its investor relations email address is [email protected]. The official website for RenovoRx is www.renovorx.com. Learn More about contacing RenovoRx investor relations.